Horan Securities’s Haemonetics HAE Stock Holding History

Horan Securities’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8	Closed	-$629	–	780
2022 Q4	$629	Buy	+8	New	+$643	﹤0.01%	680

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horan Securities's HAE Position: Q1 2023 in Review

Horan Securities sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 8 shares — an estimated $629 sold.

Horan Securities first reported a position in HAE in Q4 2022 and held it in 1 quarter. The position peaked at $629 in Q4 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

Horan Securities reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
Horan Securities sold 8 Haemonetics shares in Q1 2023, an estimated $629.
Horan Securities first reported a position in Haemonetics in Q4 2022 and held it in 1 quarter.
Horan Securities's Haemonetics position peaked at $629 in Q4 2022.
301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Horan Securities's 13F filing for Q1 2023, filed 18 Apr 2023.